Treatment with anti-GD2 monoclonal antibodies (MAb) administered intravenously, particularly the anti-GD2 IgG antibodies (ch14.18 and murine 3F8), especially in combination with interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), and oral 13-cis-retinoic acid (CRA), can effectively alleviate symptoms in high-risk NB patients. This evidence concerns the gene CSF2 and neuroblastoma.